We spoke to Dr Jagmeet Singh (Associate Chief, Cardiology Division, Massachusetts General Hospital, Boston, MA, USA) at the recent Heart Rhythm 2019 about the findings of the Multicenter Automatic Defibrillator Implantation Trial – Chemotherapy-induced Cardiomyopathy (MADIT CHIC) and how they might be interpreted in practice. Dr Singh also touches on the current unmet needs in chemotherapy-induced cardiomyopathy.
Filmed at Heart Rhythm 2019, San Francisco, CA, USA.
Speaker’s Disclosures: Jagmeet Singh consults for Abbott, Back Beat, Biotronik, Boston Scientific, EBR, Impulse Dynamics, Medtronic, Microport and Toray, and received research grants from Abbott and Boston Scientific. The study discussed was supported by an investigator-initiated research grant from Boston Scientific.
Questions:
1. What were the findings of the Multicenter Automatic Defibrillator Implantation Trial ‒ Chemotherapy-induced Cardiomyopathy (MADIT CHIC) study? (0:09)
2. How should these findings be interpreted in practice and how can they help optimise treatment selection in this patient population? (1:49)
3. What are the current unmet needs in chemotherapy-induced cardiomyopathy? (2:35)
touchCARDIO.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Filmed in partnership with Arrhythmia Alliance.
